|Other Names||EGF-containing fibulin-like extracellular matrix protein 2, Fibulin-4, FIBL-4, Protein UPH1, EFEMP2, FBLN4|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP8830a was selected from the C-term region of human EFEMP2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
A large number of extracellular matrix proteins have been found to contain variations of the epidermal growth factor (EGF) domain and have been implicated in functions as diverse as blood coagulation, activation of complement and determination of cell fate during development. EFEMP2 contains four EGF2 domains and six calcium-binding EGF2 domains.
Xiang,Y., et.al., J. Immunol. 176 (5), 3196-3204 (2006)Hucthagowder,V., et.al., Am. J. Hum. Genet. 78 (6), 1075-1080 (2006)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.